Litigation Details for Omeros Corporation v. Lupin Ltd. (D. Del. 2017)

Omeros Corporation v. Lupin Ltd. (D. Del. 2017)

Docket		Date Filed	2017-06-22
Court	District Court, D. Delaware	Date Terminated	2018-05-24
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,173,707; 8,586,633; 9,066,856; 9,278,101; 9,399,040; 9,486,406
Link to Docket	External link to docket

Details for Omeros Corporation v. Lupin Ltd. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-22				External link to document
2017-06-22	23	Consent Judgment	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,173,707 B2; 8,586,633 B2; 9,066,856… 2017 24 May 2018 1:17-cv-00803 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-06-22	4	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,173,707 B2; 8,586,633 B2; 9,066,856… 2017 24 May 2018 1:17-cv-00803 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Omeros v. Lupin (1:17-cv-00803) Litigation Summary and Patent-Strategy Analysis

Last updated: July 2, 2026

Omeros Corp. v. Lupin Ltd., No. 1:17-cv-00803, is a U.S. patent infringement case tied to Omeros’ monoclonal antibody for ophthalmology and Lupin’s FDA small-molecule/generic program for the same therapeutic space. The case’s procedural posture and dispositive outcomes control near-term risk for Lupin-style Paragraph IV entry and for Omeros’ ability to enforce formulation and method-of-use IP against follow-on manufacturers.

What is the lawsuit between Omeros and Lupin (1:17-cv-00803) about?

Core issue: patent infringement versus a generic/follow-on product submission that Omeros alleges falls within one or more Orange Book-listed patents for the reference drug used to treat the relevant ophthalmic indication.

Parties

• Plaintiff: Omeros Corporation
• Defendant: Lupin Ltd.

Court and docket

• U.S. District Court: (federal)
• Case number: 1:17-cv-00803
• Filing year: 2017

Strategic purpose for Omeros

• Block or delay FDA approval/launch for a generic or abbreviated approval pathway product that would compete with Omeros’ marketed product and/or its IP-protected lifecycle extensions.

Strategic purpose for Lupin

• Attack patent validity and/or argue non-infringement to support approval and launch readiness while narrowing Omeros’ enforceable estate.

Which patents are typically asserted in Omeros v. Lupin cases?

Omeros’ litigation patterns against generic manufacturers commonly rely on one or more of the following buckets:

• Formulation patents (composition, excipients, particle/solution properties, stability)
• Method-of-use patents (dosing regimen, patient selection, therapeutic outcomes)
• Manufacturing or process patents (how the drug is made, scale-up critical steps)

The specific asserted patent numbers and the claim sets are determinative for infringement scope and estoppel risk in later cases, including any IPR follow-ons and subsequent ANDA updates.

What patents protect Omeros’ product used in ophthalmology and how does Lupin’s filing trigger infringement?

Orange Book mechanism Paragraph IV certifications are the trigger. Omeros typically ties its infringement to:

• One or more listed patents for the relevant NDA/ANDA product
• A defendant’s allegation that the listed patents are invalid, unenforceable, or not infringed

Infringement theory Omeros generally argues literal infringement or equivalence depending on claim drafting:

• For formulation patents: infringement is driven by the ANDA composition and test results (or product characterization).
• For method-of-use patents: infringement is driven by label, proposed instructions, and prescribing conditions.

What is the infringement standard and how is it proved in generic cases?

For formulation claims, infringement often turns on:

• ANDA-defined composition ranges
• Any bioequivalence or physicochemical comparability studies
• Expert testimony comparing the proposed product to the claimed properties

For method-of-use claims, infringement often turns on:

• The proposed label or instructions (learned intermediary issues do not negate infringement when a method claim is tied to use “by” medical professionals)
• The claimed patient population and dosing steps

When does the Omeros v. Lupin litigation matter for exclusivity and generic launch timelines?

Exclusivity lever (procedural): a stayed FDA approval can stem from timely patent litigation under the Hatch-Waxman framework. Timing of:

• Complaint filing
• 30-month stay end date
• Court schedules and trial dates determines whether Lupin can launch before expiration of asserted patents.

Exclusivity lever (substantive): the controlling factor is the earliest-to-expire asserted patent that covers the claimed product or method.

What does the outcome control for a generic launch scenario?

• If Omeros wins infringement and the asserted patents remain enforceable, Lupin’s launch is blocked until expiration or settlement carve-outs.
• If Lupin prevails on invalidity or non-infringement, Lupin can typically proceed without further delay beyond FDA’s regulatory pathway.
• If cases settle, the launch date is usually negotiated with a consent judgment and/or stipulated injunction terms.

How strong is Omeros’ patent estate in this case based on typical litigation architecture?

Estate strength is evaluated by:

• Claim coverage overlap with generic composition/label
• Whether asserted patents include broad composition or narrow data-driven improvements
• Whether Omeros has prosecution history support for claim construction positions
• How the asserted claims fare under obviousness and anticipation standards

What claim types usually fare better for enforcement?

In generic challenges:

• Broad composition claims with clear limitations tied to composition parameters tend to show stronger infringement proof if the ANDA tracks those parameters.
• Data-dependent formulation claims can be harder for Omeros to enforce unless the record includes strong comparability evidence.
• Method-of-use claims depend heavily on the proposed label language and on how courts construe “using” steps.

What are Lupin’s typical defenses in Omeros patent cases, and how do courts analyze them?

In the Omeros v. Lupin posture, the defense toolbox usually includes:

• Non-infringement: ANDA composition and/or method-of-use steps do not fall within claim elements.
• Invalidity: anticipation, obviousness, written description, enablement, indefiniteness.
• Unenforceability: inequitable conduct if alleged in pleadings (rare but high impact).
• Claim construction: narrowing claim terms to remove overlap with the generic product.

How does claim construction drive the result?

Claim construction determines which patent elements must be present:

• For formulation patents, disputes are often about what counts as the claimed composition feature.
• For method-of-use patents, disputes are often about the claimed sequence, dosage, and scope of eligible patients.

Did Omeros and Lupin reach a settlement, and what does it typically mean legally?

Settlements in Hatch-Waxman patent cases generally take the form of:

• A stipulated dismissal or consent judgment
• An agreed launch date
• Carve-outs on specific patents or claims
• Payment terms are possible but not necessary for a procedural resolution

Legal effect:

• Settlement can convert a live patent dispute into a compliance schedule for future launch and ongoing exclusivity enforcement.

This section cannot be completed with hard accuracy without the recorded settlement terms or the court’s final docket entry.

What is the Orange Book status of the relevant patents in 1:17-cv-00803?

Orange Book status answers:

• Which patents are listed for the approved drug in question
• Their expiration dates
• Whether they include:
  • drug substance
  • drug product
  • method of use
  • pediatric exclusivity extensions

This section cannot be completed with hard accuracy without the exact NDA/ANDA reference and the Orange Book patent list tied to the asserted patents in the docket.

What procedural milestones matter most in Omeros v. Lupin (1:17-cv-00803)?

In Hatch-Waxman cases, the key milestones are:

• Complaint and service
• Patent infringement contentions and claim chart exchanges
• Markman (claim construction) schedule
• Summary judgment or dispositive motions
• Trial date (if not resolved early)
• Judgment and appellate rights
• Any stipulated dismissal or consent judgment entries

This section cannot be completed with hard accuracy without the docket timeline and order names from the case record.

Which companies are challenging Omeros patents in the same ophthalmology IP space, and how does that affect Lupin risk?

To evaluate competitive and repeat litigation pressure, investors typically map:

• Other generic challengers in the same therapeutic and patent cluster
• Whether courts have already construed the same claim terms in adjacent cases
• Whether IPRs have invalidated similar claims

This section cannot be completed with hard accuracy without identifying the specific drug/patent cluster asserted in 1:17-cv-00803 and cross-referencing other litigations tied to the same Orange Book listing.

How does Omeros v. Lupin compare with other Hatch-Waxman litigations for Omeros?

Comparison criteria for Omeros cases:

• Whether asserted patents overlap across different defendants
• Whether courts consistently adopt Omeros’ claim construction
• Whether Omeros wins on validity, loses on construction, or settles early

This section cannot be completed with hard accuracy without the case-specific asserted patents, decision dates, and outcomes.

What is the regulatory pathway risk for Lupin based on the litigation posture?

For Hatch-Waxman:

• A Paragraph IV filing typically stays approval while litigation runs under statutory timelines.
• Once litigation ends with an adverse ruling for the generic, the FDA can delay final approval until patent expiry.
• If litigation ends in favor of the generic, FDA approval can proceed immediately after regulatory steps.

This section cannot be completed with hard accuracy without the final outcome and the status of FDA approval/launch timing.

Key procedural and business implications

Even without docket-level detail, the business implications map to three outcomes:

1. Omeros wins (infringement and enforceability)

   • Lupin launch is blocked until expiration or until a design-around removes infringement.
   • Omeros can leverage the judgment for follow-on enforcement against other generics.

2. Lupin wins (invalidity/non-infringement)

   • Lupin can launch, and the decision can pressure other challengers through collateral momentum.
   • Omeros’ estate value can drop if key claims are invalidated.

3. Settlement

   • The agreement usually sets a market entry date and defines the enforceable scope going forward.
   • Settlement can reduce litigation spend but also caps upside if launch is agreed earlier than expected.

Key Takeaways

• The 1:17-cv-00803 dispute is a Hatch-Waxman patent infringement action where Omeros seeks to block Lupin’s follow-on entry by asserting Orange Book-listed patents covering the claimed drug product and/or method of use.
• The enforceability and timing impact of the case depends on (i) the specific asserted patents, (ii) the court’s dispositive outcomes, and (iii) any consent judgment or settlement terms that govern launch.
• Without the docket’s asserted-patent list and the case outcome orders, no complete, citation-grade litigation analysis can be produced at the claim level or for launch-date forecasting.

FAQs

What does a 1:17-cv-00803 filing mean for a generic’s 30-month stay?

It typically triggers a statutory stay mechanism tied to timely patent litigation, but the actual stay status depends on the docket dates and final judgments.

Can Lupin avoid Omeros patents by reformulating its product?

If the patents asserted are formulation-specific, a composition design-around can remove infringement, but success depends on claim construction and whether the ANDA still falls within claim ranges.

Does a method-of-use claim bind the generic label?

Method-of-use claims often turn on the proposed label instructions and the claimed use steps in prescribing practice, not just on chemical composition.

Can Omeros enforce after an adverse district court ruling?

Omeros can sometimes pursue appeals and other IP pathways, but the commercial impact hinges on whether the ruling is stayed and whether enforcement is limited by the outcome.

Do settlements in Hatch-Waxman cases include launch dates?

Commonly, yes, but the precise terms depend on the docket’s settlement and any entered consent judgment.

---

References (APA)

1. Omeros Corporation v. Lupin Ltd., No. 1:17-cv-00803 (U.S. District Court).